Home | Publications | Healthcare place holder
place holder place holder

Healthcare

Novo Nordisk A/S: PharmaVitae Profile


Publication Date   July 2008
Publisher   Datamonitor
Product Type   Report
Pages   139
ISBN Number   not applicable
Product Code   DAT1475
Ask a question about this product?

Price £2,995.00

approximately: $4,466 | €3,568

Summary


Introduction

This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Novo Nordisk's performance against key rivals in the ethical pharmaceutical sector
  • Analyze how Novo Nordisk's strong position in the diabetes market will position the company within the Big Pharma peer set by 2011
  • Assess the company's highly focused strategy, centred on diabetes treatments, the use of therapeutic proteins and internally sourced R&D productivity

Content


  • Chapter 1 About This Profile
    • Executive Summary
    • Quarterly News Update
    • Company Introduction
    • Company Sales
    • Company Financials
    • Key Products And Competitors
    • Data Sourcing
    • Sales Data
    • Analyst Consensus
  • Chapter 2 Executive Summary
    • Key Findings
    • Prescription Pharmaceutical Sales Performance, 2001-13
    • Financial Performance, 2001-13
    • Novo Nordisk: Pharmavitae Forecasts At A Glance
    • Strategic Insight
    • Novo Nordisk - A Focus Strategy Company
    • Big Pharma Status From 2011
    • Swot Analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 3 Quarterly News Update
    • Product Developments
    • Deals And Alliances
    • Product Deals
    • Technology Deals
    • M&A Activity
    • Company Announcements
    • Future Product Milestones
  • Chapter 4 Company Structure
    • Key Findings
    • Company Overview
    • Company History
    • M&A History
    • Nordisk Gentofte And Novo Industri Merger
    • Divestments Promote Rx Pharma Focus
    • Novo Nordisk And Novozymes Demerger
    • Demerger Of Zymogenetics
    • Acquisition Of Biobrs And Pharmaplan Gmbh
  • Chapter 5 Company Sales
    • Key Findings
    • Prescription Pharmaceutical Sales And Growth Rate Analysis, 2001-13
    • Product Analysis
    • Product Analysis, 2001-07
    • Product Analysis, 2007-13
    • Therapy Area Analysis
    • Therapy Area Analysis, 2001-07
    • Therapy Area Analysis, 2007-13
    • Therapy Area Focus, 2001-13
    • Geographic Analysis
    • Geographic Analysis, 2001-07
    • Geographic Analysis, 2007-13
    • Geographic Focus, 2001-13
    • Launch/Core/Expiry Analysis
    • Explanation Of Launch/Core/Expiry Analysis
    • Launch Analysis, 2007-13
    • Core Analysis, 2007-13
    • Expiry Analysis, 2007-13
    • Launch/Core/Expiry Configuration, 2007-13
    • Molecule Type Analysis
    • Molecule Type Analysis, 2001-07
    • Molecule Type Analysis, 2007-13
    • Molecule Type Focus, 2001-13
    • Externalization Analysis
    • Externalization Analysis, 2001-07
    • Externalization Analysis, 2007-13
  • Chapter 6 Company Financials
    • Key Findings
    • Reconciliation Between Pharmavitae-Formatted Prescription Pharma Sales And Company-Reported Total Sales, 2001-07
    • Financial Statements, 2001-07
    • Profit And Loss Account, 2001-07
    • Balance Sheet, 2001-07
    • Operating Costs And Profit Analysis
    • Operating Costs And Profit Analysis, 2001-07
    • Operating Cost Ratio And Profit Margin Analysis, 2001-07
    • Operating Cost Ratio And Profit Margin Analysis, 2007-13
    • Operating Costs And Profit Analysis, 2007-13
    • Return On Capital Employed Analysis
    • Capital Employed Analysis, 2001-07
    • Return On Capital Employed (Roce) Analysis, 2001-07
    • Market Capitalization Analysis
    • Market Capitalization Analysis, 2001-07
    • Total Shareholder Returns Analysis, 2001-07
  • Chapter 7 Key Products And Competitors
    • Key Findings
    • Overview
    • Diabetes Market Overview
    • Definition Of Diabetes
    • Key Antidiabetic Product Classes
    • Key Competitors To Novo Nordisk''s Antidiabetics Portfolio
    • Endocrine, Metabolic And Genetic Disorders
    • Novorapid/Novolog
    • Novomix
    • Levemir
    • Liraglutide
    • Norditropin
    • Hematology
    • Novoseven
  • Chapter 8 Appendix
    • R&D Pipeline
    • References
    • Abbreviations
    • Exchange Rates
  • Table Of Tables
    • Table 1: Novo Nordisk - Pharmavitae Forecasts At A Glance
    • Table 2: Novo Nordisk Key Product Developments, 2008
    • Table 3: Novo Nordisk Product Deals And Alliances, 2008
    • Table 4: Novo Nordisk Technology Deals And Alliances, 2008
    • Table 5: Novo Nordisk M&A Activity, 2008
    • Table 6: Novo Nordisk Company Announcements, 2008
    • Table 7: Novo Nordisk Future Product Milestones, 2008-10
    • Table 8: Novo Nordisk Product Portfolio Overview ($M), 2001-07
    • Table 9: Novo Nordisk Product Portfolio Overview ($M), 2007-13
    • Table 10: Novo Nordisk Therapy Portfolio Overview ($M), 2001-07
    • Table 11: Novo Nordisk Therapy Portfolio Overview ($M), 2007-13
    • Table 12: Novo Nordisk Portfolio Overview By Geographic Region ($M), 2001-07
    • Table 13: Novo Nordisk Portfolio Overview By Geographic Region ($M), 2007-13
    • Table 14: Prevalence Of Diabetes Mellitus By Major Market (Millions)
    • Table 15: Novo Nordisk Launch Portfolio Overview ($M), 2007-13
    • Table 16: Novo Nordisk Core Portfolio Overview ($M), 2007-13
    • Table 17: Novo Nordisk Expiry Portfolio Overview ($M), 2007-13
    • Table 18: Novo Nordisk Portfolio Overview By Molecule Type ($M), 2001-07
    • Table 19: Novo Nordisk Product Portfolio Overview By Molecule Type ($M), 2007-13
    • Table 20: Novo Nordisk Product Portfolio Overview By Source ($M), 2001-07
    • Table 21: Novo Nordisk Product Portfolio Overview By Source ($M), 2007-13
    • Table 22: Total Novo Nordisk Sales By Business Unit ($M), 2001-07
    • Table 23: Novo Nordisk Profit And Loss Account ($M), 2001-07
    • Table 24: Novo Nordisk Balance Sheet ($M), 2001-07
    • Table 25: Novo Nordisk Operating Revenue/Cost Analysis ($M), 2001-07
    • Table 26: Novo Nordisk Operating Cost Ratio Analysis (% Of Total Revenues), 2001-07
    • Table 27: Novo Nordisk Operating Cost Ratio Analysis (% Of Total Revenues), 2007-13
    • Table 28: Novo Nordisk Operating Revenue/Cost Analysis ($M), 2007-13
    • Table 29: Novo Nordisk Capital Employed ($M), 2001-07
    • Table 30: Novo Nordisk Ebit Return On Capital Employed ($M), 2001-07
    • Table 31: Novo Nordisk Ebit Pre-Tax Return/Capital Employed Driver Analysis (%), 2001-07
    • Table 32: Novo Nordisk Market Capitalization ($ Billion), 2001-07
    • Table 33: Novo Nordisk Total Shareholder Returns (Annual %), 2001-07
    • Table 34: Key Products Overview
    • Table 35: Key Insulin Antidiabetics In 2007
    • Table 36: Key Non-Insulin Antidiabetics In 2007
    • Table 37: Novorapid/Novolog: Overview
    • Table 38: Novorapid/Novolog: Sales Forecast ($M), 2007-13
    • Table 39: Novomix: Overview
    • Table 40: Novomix: Sales Forecast ($M), 2007-13
    • Table 41: Levemir: Overview
    • Table 42: Levemir: Sales Forecast ($M), 2007-13
    • Table 43: Liraglutide: Overview
    • Table 44: Liraglutide: Sales Forecast ($M), 2007-13
    • Table 45: Norditropin: Overview
    • Table 46: Norditropin: Sales Forecast ($M), 2007-13
    • Table 47: Novoseven: Overview
    • Table 48: Novoseven: Sales Forecast ($M), 2007-13
    • Table 49: Key Hemophilia Products In 2007
    • Table 50: Novo Nordisk''s R&D Pipeline (Phase I-registration)
    • Table 51: Novo Nordisk''s Lifecycle Management Pipeline (Phase I-registration)
    • Table 52: Exchange Rates, 2007
  • Table Of Figures
    • Figure 1: Novo Nordisk Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 2001-13
    • Figure 2: Novo Nordisk Financial Performance ($M), 2001-13
    • Figure 3: Novo Nordisk Focus Strategy, 2001-13
    • Figure 4: Novo Nordisk Swot Analysis
    • Figure 5: Novo Nordisk Company History
    • Figure 6: Novo Nordisk Corporate Structure
    • Figure 7: Novo Nordisk Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 2001-13
    • Figure 8: Novo Nordisk Key Sales Growth Driver & Resistors ($M), 2001-07
    • Figure 9: Novo Nordisk Key Sales Growth Drivers & Resistors ($M), 2007-13
    • Figure 10: Novo Nordisk Prescription Pharmaceutical Sales By Therapy Area ($M), 2001-13
    • Figure 11: Novo Nordisk Prescription Pharma Sales By Therapy Area (% Of Total), 2001-13
    • Figure 12: Novo Nordisk Prescription Pharmaceutical Sales By Geographic Region ($M), 2001-13
    • Figure 13: Novo Nordisk Drivers And Resistors By Geographic Region ($M), 2001-07
    • Figure 14: Novo Nordisk Drivers And Resistors By Geographic Region ($M), 2007-13
    • Figure 15: Novo Nordisk Prescription Pharmaceutical Sales By Geographic Region (% Of Total), 2001-13
    • Figure 16: Novo Nordisk Launch/Core/Expiry Configuration ($M), 2007-13
    • Figure 17: Novo Nordisk Prescription Pharmaceutical Sales By Molecule Type ($M), 2001-13
    • Figure 18: Novo Nordisk Growth Drivers & Resistors By Molecule Type ($M), 2007-13
    • Figure 19: Novo Nordisk Prescription Pharmaceutical Sales By Molecule Type (% Of Total), 2001-13
    • Figure 20: Novo Nordisk Prescription Pharmaceutical Sales By Source ($M), 2001-13
    • Figure 21: Novo Nordisk Growth Drivers & Resistors By Source ($M), 2001-07
    • Figure 22: Novo Nordisk Growth Drivers & Resistors By Source ($M), 2007-13
    • Figure 23: Novo Nordisk Operating Revenue/Cost Analysis ($M), 2001-13
    • Figure 24: Novo Nordisk Operating Cost Ratio Analysis (% Of Total Revenues), 2001-13
    • Figure 25: Novo Nordisk Return On Capital Employed, Ebit Margin And Capital Turnover, 2001-07
    • Figure 26: Return On Capital Employed Formula
    • Figure 27: Novo Nordisk Market Capitalization ($ Billion), 2001-07
    • Figure 28: Novo Nordisk Total Shareholder Returns Vs. S&P 500 ($M), 2001-07
    • Figure 29: Novo Nordisk: Key Competitors In The Antidiabetics Market